Eleison is seeking an entrepreneurial, hands-on, success-driven individual to lead partnering and licensing efforts for our three late-stage cancer programs. We are not looking for an "employee", but rather a key member of our management team, motivated by the accomplishment of bringing new and much needed therapeutics to the clinic, and participating in the building of equity value.
We are a clinical stage, specialty pharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapeutics to address areas of high unmet medical need in the treatment of rare cancers. We leverage our considerable industry experience, oncology therapeutics knowledge and development expertise to identify drug candidates we believe have strong market potential and to design highly efficient clinical programs. Our substantial intellectual property and “orphan drug designations” in the United States and Europe maximizes market exclusivity. Our current portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD).
Our lead program, glufosfamide, is in development for pancreatic cancer, the third leading cause of cancer deaths in the United States according to the American Cancer Society. Our ongoing pivotal Phase III study for glufosfamide in second-line pancreatic cancer is expected to be completed and a planned NDA filing in 2025. Our second program, ILC, is in development for small cell lung cancer and pediatric bone cancer (osteosarcoma). A Phase III trial for patients with lung cancer and ...a potentially pivotal Phase II/III study of patients with osteosarcoma are expected to commence in 2023 and 2025, respectively. Our newest program, dibromodulcitol, is in development for brain cancer (e.g., glioblastoma), with a pivotal Phase III trial planned to begin in 2024.
For more information, please visit our website www.eleison-pharma.com .